Literature DB >> 12531481

Cloning and characterization of the SIL promoter.

Tina Colaizzo-Anas1, Peter D Aplan.   

Abstract

The SIL gene undergoes a site-specific rearrangement with the SCL gene in 25% of patients with T cell acute lymphoblastic leukemia (ALL). The functional result of this rearrangement is that the SIL regulatory elements aberrantly drive expression of the SCL gene. We have cloned and sequenced the human SIL promoter, cloned a murine homolog, found the sequence to be highly conserved, and defined a minimal promoter region. Both the cloned murine and human sequences were found to be highly active in either human or murine cells. SCL mRNA, driven by a cloned SIL promoter, could be downregulated by DMSO in stably transfected F4-6 murine erythroleukemia cells. The SIL promoter was found to be partially unmethylated in proliferating tissues, in which it is highly expressed, and more highly methylated in post-mitotic tissues, in which SIL is not expressed. The isolation of the SIL promoter provides an important tool for the study of both the SIL gene expression as well as the role of the SIL promoter in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531481     DOI: 10.1016/s0167-4781(02)00597-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Cre-loxP-mediated recombination between the SIL and SCL genes leads to a block in T-cell development at the CD4- CD8- to CD4+ CD8+ transition.

Authors:  Yue Cheng; Zhenhua Zhang; Christopher Slape; Peter D Aplan
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

2.  The mitotic checkpoint gene, SIL is regulated by E2F1.

Authors:  Ayelet Erez; Marie Chaussepied; Asher Castiel; Tina Colaizzo-Anas; Peter D Aplan; Doron Ginsberg; Shai Izraeli
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

3.  In silico prediction of a disease-associated STIL mutant and its affect on the recruitment of centromere protein J (CENPJ).

Authors:  Ambuj Kumar; Vidya Rajendran; Rao Sethumadhavan; Rituraj Purohit
Journal:  FEBS Open Bio       Date:  2012-09-25       Impact factor: 2.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.